BUZZ-IntelliPharmaceuticals International: Research action
** Canadian drugmaker's U.S.-listed shares up 16 pct at $3.15
** Maxim Group analysts upgrade stock to "buy" and raised price target to $7 from $3
** "Based on our estimates of the numerous phase I trials now underway, we believe we could see Rexista (pain-killer drug) expedited in the marketplace much faster than we previously expected," analyst wrote in a note
** Up to Thursday's close, stock has fallen 27 percent this year
© Thomson Reuters 2017 All rights reserved.